Low Dose Celecoxib Combined with Clozapine for Treatment of Schizophrenia: A Double Blind Randomized Clinical Trial

Authors

  • Amin Azhari Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Mehri Baghban Haghighi Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Roya Samadi Department of Psychiatry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Shervin Assari Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran|Department of Psychiatry, School of Public Health, University of Michigan, Ann Arbor, USA
Abstract:

Introduction: Higher levels of pro-inflammatory cytokines in schizophrenia have suggested that dysfunctions of the immune system may play a role in this disabling condition. The current study was performed to discover if low dose celecoxib combined with clozapine may improve symptoms of schizophrenia or not. Methods: In a double-blind randomized clinical trial, 40 patients with non- treatment resistance schizophrenia were allocated into two groups. The experimental group received flexible and low dose clozapine plus 200 mg/day of celecoxib for 4 weeks, while the control group received clozapine plus placebo. Experimental and control groups were similar in terms of age, gender, clozapine mean dosage and severity of schizophrenic symptoms at baseline. Main outcomes were severity of schizophrenia symptoms measured by the Positive and Negative Syndrome Scale (PANSS) at baseline followed by the second and fourth weeks. Results: Although both groups experienced significant improvement in all PANSS sub-scales in the second and fourth weeks (P<0.001), the differences between the two groups did not reach significance (P>0.05). Conclusion: Our findings did not support the findings of prior studies that report a significant effect for celecoxib combined with atypical antipsychotics. Such inconsistency may be due to statistical power, drug interactions between clozapine and celecoxib, and the low dose of celecoxib used in this study. Future research is needed on the role of anti-inflammatory medications as adds-on treatments for schizophrenia.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Celecoxib or Prednisolone for Treatment of Medication Overuse Headache: A Randomized, Double-Blind Clinical Trial in Migrainous Patients

Background:Treatment of Medication Overuse Headache (MOH) is yet under debate and Celecoxib as a Cyclooxygenase 2 (COX2) -inhibitor has not been tried widely as a pain relief drug for this type of headaches in migrainous patients.&nbsp; Objectives: comparing the efficacy of celecoxib versus prednisolone for withdrawal period of MOH. Materials & Methods: A double-blind, randomized clinical tri...

full text

Treatment-Responsiveness of Negative Symptoms in Schizophrenia: A double-blind placebo-control clinical trial

Background: The negative symptoms of schizophrenia remain a major clinical challenge. Nortriptyline is a serotonin and noradrenalin reuptake inhibitor and belongs to secondary amine tricycles. The aim of this study is to evaluate the effect of nortriptyline on the negative symptoms of schizophrenia. Methods: This study is a six-week randomized placebo-control trial of nortriptyline or placebo a...

full text

Effectiveness of Prophylactic Celebrex and Celecoxib Administration for Controlling Post-endodontic Pain: A Randomized Double-blind Clinical Trial

Introduction Pain control following root canal therapy is a challenging issue in dentistry. This double-blind study aimed to compare the effectiveness of Celebrex and celecoxib used to control post-endodontic pain. Material and Methods In this randomized, double-blind study, 43 patients with symptomatic teeth were selected. The subjects gave their consent for a prophylactic oral administrati...

full text

A Randomized Double Blind Clinical Trial in Famotidine Adjuvant Therapy in Schizophrenia

Background: About 40%-60% of schizophrenic patients are resistant to ordinary treatment, which result from interference with different neurotransmitter systems in the process of disease. The aim of present study was to determine the effect of famotidine on several symptoms of schizophrenia which was nonresponsive to neuroleptic treatment. Methods: 30 schizophrenic patients previously nonrespons...

full text

Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder

BACKGROUND One of the major causes of death in schizophrenia is a metabolic syndrome. The clozapine has the highest rate of weight gain among antipsychotics. It has been shown that metformin can promote weight loss. We aimed to investigate the effect of metformin as an adjunctive therapy with clozapine to prevent metabolic syndrome in patients with schizophrenia. MATERIALS AND METHODS A total...

full text

Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial

Objective: Saffron was found efficient and safe in treatment of neuropsychiatric disorders, in particular depression. We compared the efficacy of saffron with duloxetine in treatment of patients with fibromyalgia. Materials and Methods: In this double-blind parallel-group clinical trial, outpatients with fibromyalgia were randomized to receive either saffron 15 mg or duloxetine 30 mg starting w...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 3  issue 1

pages  11- 17

publication date 2015-02-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023